VB-201
Code | Size | Price |
---|
TAR-T29099-5mg | 5mg | £711.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T29099-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T29099-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
VB-201, a Toll-like receptor-2 (TLR-2) antagonist, is used potentially for the treatment of atherosclerosis.
CAS:
630112-41-3
Formula:
C29H60NO8P
Molecular Weight:
581.772
Purity:
0.98
SMILES:
CCCCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCC(O)=O
References
1. Mendel I, Feige E, Yacov N, Salem Y, Levi I, Propheta-Meiran O, Shoham A, Ishai E, George J, Harats D, Breitbart E. VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014 Jan;175(1):126-37. doi: 10.1111/cei.12212. PubMed PMID: 24116867; PubMed Central PMCID: PMC3898561.
2. Feige E, Yacov N, Salem Y, Levi I, Mendel I, Propheta-Meiran O, Shoham A, Hait-Darshan R, Polonsky O, George J, Harats D, Breitbart E. Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE?/? mice. Atherosclerosis. 2013 Aug;229(2):430-9. doi: 10.1016/j.atherosclerosis.2013.06.005. PubMed PMID: 23880199.
3. Mendel I, Shoham A, Propheta-Meiran O, Ishai E, Halperin G, Feige E, Breitbart E. A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease. J Neuroimmunol. 2010 Sep 14;226(1-2):126-35. doi: 10.1016/j.jneuroim.2010.06.011. PubMed PMID: 20663571.
4. Mendel I, Yacov N, Shoham A, Ishai E, Breitbart E. Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. Dig Dis Sci. 2016 Sep;61(9):2545-53. doi: 10.1007/s10620-016-4159-5. PubMed PMID: 27074921; PubMed Central PMCID: PMC4980417.